186 related articles for article (PubMed ID: 34605602)
1. Genetic alteration and clonal evolution of primary glioblastoma into secondary gliosarcoma.
Li J; Zhao YH; Tian SF; Xu CS; Cai YX; Li K; Cheng YB; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Dec; 27(12):1483-1492. PubMed ID: 34605602
[TBL] [Abstract][Full Text] [Related]
2. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
[TBL] [Abstract][Full Text] [Related]
3. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clonal evolution in recurrent metastatic gliosarcoma.
Anderson KJ; Tan AC; Parkinson J; Back M; Kastelan M; Newey A; Brewer J; Wheeler H; Hudson AL; Amin SB; Johnson KC; Barthel FP; Verhaak RGW; Khasraw M
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 31896544
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
7. Transformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
[TBL] [Abstract][Full Text] [Related]
9. Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
Vuong HG; Dunn IF
J Neurooncol; 2022 Aug; 159(1):195-200. PubMed ID: 35768633
[TBL] [Abstract][Full Text] [Related]
10. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Kiang KM; Chan AA; Leung GK
BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Cho SY; Park C; Na D; Han JY; Lee J; Park OK; Zhang C; Sung CO; Moon HE; Kim Y; Kim JH; Kim JJ; Khang SK; Nam DH; Choi JW; Suh YL; Kim DG; Park SH; Youn H; Yun K; Kim JI; Lee C; Paek SH; Park H
Exp Mol Med; 2017 Apr; 49(4):e317. PubMed ID: 28408749
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components.
Actor B; Cobbers JM; Büschges R; Wolter M; Knobbe CB; Lichter P; Reifenberger G; Weber RG
Genes Chromosomes Cancer; 2002 Aug; 34(4):416-27. PubMed ID: 12112531
[TBL] [Abstract][Full Text] [Related]
13. An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.
Sato Y; Deguchi S; Norose T; Oishi T; Mitsuya K; Sugino T; Akiyama Y; Nagashima T; Urakami K; Shimoda Y; Ohshima K; Hayashi N; Yamaguchi K
Nagoya J Med Sci; 2023 Nov; 85(4):828-835. PubMed ID: 38155632
[TBL] [Abstract][Full Text] [Related]
14. Secondary gliosarcoma with extra-cranial metastases: a report and review of the literature.
Dawar R; Fabiano AJ; Qiu J; Khushalani NI
Clin Neurol Neurosurg; 2013 Apr; 115(4):375-80. PubMed ID: 22795300
[TBL] [Abstract][Full Text] [Related]
15. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
Abou-El-Ardat K; Seifert M; Becker K; Eisenreich S; Lehmann M; Hackmann K; Rump A; Meijer G; Carvalho B; Temme A; Schackert G; Schröck E; Krex D; Klink B
Neuro Oncol; 2017 Apr; 19(4):546-557. PubMed ID: 28201779
[TBL] [Abstract][Full Text] [Related]
17. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.
Chen Y; Zhou S; Zhou X; Dai X; Wang L; Chen P; Zhao S; Shi C; Xiao S; Dong J
Pathol Res Pract; 2022 Apr; 232():153837. PubMed ID: 35278815
[TBL] [Abstract][Full Text] [Related]
18. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma.
Georgescu MM; Olar A
Acta Neuropathol Commun; 2020 Feb; 8(1):10. PubMed ID: 32014051
[TBL] [Abstract][Full Text] [Related]
19. Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.
Cheng CD; Chen C; Wang L; Dong YF; Yang Y; Chen YN; Niu WX; Wang WC; Liu QS; Niu CS
Anal Cell Pathol (Amst); 2022; 2022():2376288. PubMed ID: 35757013
[TBL] [Abstract][Full Text] [Related]
20. Treatment-associated
Pain M; Wang H; Lee E; Strahl M; Hamou W; Sebra R; Zhu J; Yong RL
Oncotarget; 2018 Jan; 9(2):2603-2621. PubMed ID: 29416795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
